Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 1/2 6Phase 2 4Phase NA 1Phase 3 1

Status

Completed 5Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Interventional 7

Sponsor

Cancer Type

Tumor-Agnostic 4Gastrointestinal 3Thoracic 1Lymphoid 1Genitourinary 1

Conditions

Breast Neoplasms 20Pancreatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 17Ovarian Neoplasms 16Fallopian Tube Neoplasms 12Triple Negative Breast Neoplasms 10Neoplasm Metastasis 10Carcinoma, Ovarian Epithelial 10Unspecified Adult Solid Tumor, Protocol Specific 8Neoplasms 7Lung Neoplasms 7Endometrial Neoplasms 7Esophageal Neoplasms 6Brenner Tumor 6Breast Neoplasms, Male 6Stomach Neoplasms 5Melanoma 5Squamous Cell Carcinoma of Head and Neck 4Peritoneal Neoplasms 3Gallbladder Neoplasms 3Cholangiocarcinoma 3Adenocarcinoma of Lung 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Leukemia, Lymphocytic, Chronic, B-Cell 2

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × Taxes × Clear all
NCT05382559 2026-04-14

A Study of ASP3082 in Adults With Advanced Solid Tumors

Astellas Pharma Inc

Phase 1 Recruiting
681 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT03564691 2025-10-07

MK-4830-001

Merck Sharp & Dohme LLC

Phase 1 Completed
470 enrolled
Tumor-Agnostic

Neoplasms

NCT03884556 2025-07-02

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Trishula Therapeutics, Inc.

Phase 1 Completed
56 enrolled 19 charts
GastrointestinalGenitourinaryLymphoidThoracic

Urinary Bladder Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms

NCT03918278 2025-06-25

MK-0482-001

Merck Sharp & Dohme LLC

Phase 1 Completed
222 enrolled
Tumor-Agnostic

Neoplasms

NCT05494866 2025-03-25

IntenSify

German Cancer Research Center

Phase 1 Terminated
6 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

NCT01057264 2015-11-18

HAI Abraxane With Gemcitabine and Bevacizumab

M.D. Anderson Cancer Center

Phase 1 Completed
78 enrolled
Tumor-Agnostic

Neoplasms

NCT01161186 2012-10-11

Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma

University of California, San Francisco

Phase 1 Completed
15 enrolled
Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡